Clinical Trials
Proton beam therapy yields high local control in nonmetastatic HCC, registry finds
Chuong et alAdvances in radiation oncology

Findings from the multi-institutional Proton Collaborative Group REG001-09 prospective registry study (NCT01255748) evaluate treatment outcomes and toxicity for definitive proton beam therapy (PBT) in nonmetastatic hepatocellular carcinoma (HCC) across 9 United States institutions.
The study included 88 patients treated between 2013 and 2021. Median age was 68 years (range, 40–91), and 85.0% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Median tumor size was 4.7 cm (range, 1.2–19 cm). Baseline hepatic function was Child-Pugh class A in 43 patients (71.7%) and class B in 15 patients (25.0%). PBT was administered predominantly using moderate hypofractionation, with a median prescribed total dose of 59.1 Gy(RBE) across a median of 15 fractions (range, 5–33 fractions) and a median prescribed biologically effective dose (BED10) of 86.4 Gy(RBE) (range, 48.7–144 Gy[RBE]).
At a median follow-up of 25.1 months (range, 17.5–36.8 months), estimated 2-year clinical endpoints were: • Freedom from local failure (FFLF): 93.4% (95% CI, 86.0%–100.0%) • Freedom from intrahepatic failure (FFIF): 67.3% (95% CI, 54.2%–80.4%) • Freedom from distant failure (FFDF): 91.8% (95% CI, 83.9%–99.7%) • Progression-free survival (PFS): 38.4% (95% CI, 26.5%–50.2%) • Overall survival (OS): 54.9% (95% CI, 42.4%–67.4%)
On multivariable analysis, no clinical or treatment factors were significantly associated with overall survival. Regarding safety, no grade 3 or higher toxicities were reported. These multi-institutional findings confirm that dose-escalated PBT achieves high local control with a favorable toxicity profile in Western HCC cohorts.
Key Takeaways
- In patients with nonmetastatic hepatocellular carcinoma treated with definitive proton beam therapy, the estimated 2-year freedom from local failure rate was 93.4% (95% CI, 86.0%–100.0%) and the 2-year overall survival rate was 54.9% (95% CI, 42.4%–67.4%).
- Proton beam therapy demonstrated high tolerability with no reported grade 3 or higher toxicities across the multi-institutional cohort.
- Estimated 2-year freedom from intrahepatic failure, freedom from distant failure, and progression-free survival rates were 67.3% (95% CI, 54.2%–80.4%), 91.8% (95% CI, 83.9%–99.7%), and 38.4% (95% CI, 26.5%–50.2%), respectively.
Read the original sourceAdvances in radiation oncology
